
Skape Bio is a biotechnology company revolutionizing GPCR drug discovery through AI-powered protein design and high-throughput screening technology. Their innovative platform integrates deep evolutionary insights with advanced methodologies to create novel modulators of integral membrane proteins, enabling the discovery of unique agonists and antagonists. By utilizing in-cell screening, they can evaluate thousands of designs in their natural context, accelerating the development of therapeutics for oncology, inflammation, metabolic disease, and neurology. Skape Bio, a spinout from a collaboration between the BioInnovation Institute and the University of Washington’s Institute for Protein Design, is positioned to lead in the biopharmaceutical space with its cutting-edge technology and partnerships with pharmaceutical companies.

Skape Bio is a biotechnology company revolutionizing GPCR drug discovery through AI-powered protein design and high-throughput screening technology. Their innovative platform integrates deep evolutionary insights with advanced methodologies to create novel modulators of integral membrane proteins, enabling the discovery of unique agonists and antagonists. By utilizing in-cell screening, they can evaluate thousands of designs in their natural context, accelerating the development of therapeutics for oncology, inflammation, metabolic disease, and neurology. Skape Bio, a spinout from a collaboration between the BioInnovation Institute and the University of Washington’s Institute for Protein Design, is positioned to lead in the biopharmaceutical space with its cutting-edge technology and partnerships with pharmaceutical companies.
About Skape Bio
Skape Bio is an early-stage, venture-backed biotechnology company, co-founded by Nobel Laureate David Baker to develop de novo designed miniprotein therapeutics for GPCRs. Our platform integrates computational design, protein engineering, novel screening technology and translational science deliver breakthrough medicines where significant unmet medical needs remain and traditional modalities have failed to provide a solution.
We are building a highly collaborative team where passionate individuals thrive in a hands-on, high-impact environment. Our culture is open and supportive, emphasizing initiative, teamwork, rapid learning, and high standards.
Role Overview
We are seeking an experienced and motivated DMPK leader to establish and drive the pharmacokinetic and translational strategy for Skape Bio’s miniprotein therapeutic programs. This role will focus on designing and optimizing the pharmacokinetic profiles of miniproteins, including innovative approaches to modulate half-life, clearance, and tissue distribution to achieve the desired exposure. The successful candidate will play a key role in shaping miniprotein optimization, dosing strategy, candidate selection, and early clinical translation as programs progress from discovery into development. This is an opportunity to build DMPK capability from the ground up in a modality-focused platform company.
Key Responsibilities
Qualifications
Preferred Experience
What we offer
Apply for the job
Do you want to join our team as our new Director of DMPK & Biodistribution? Then we'd love to hear from you! Apply here: https://skape-bio.homerun.co/director-of-dmpk-biodistribution/en